A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis

Inclusion Criteria: * Male or female 18 to 70 years of age. * Clinical diagnosis of stable atopic dermatitis (AD) and with two lesions of similar size and have an identical score of at least 5 but no more than 9 on the sum of the individual components of the Eczema Area and Severity Index (EASI) at the Target Lesion scale. * Male or non-pregnant, non-lactating females. * Signed informed consent. Exclusion Criteria: * Subjects who have unstable atopic dermatitis (AD). * Significant infection at the target lesion site. * Prior or concomitant use of systemic therapies for AD within the past 4 weeks. - Prior or concomitant use of topical treatments for AD, to within 10 cm of the target lesion within the past 4 weeks. * Prior or concomitant use of oral retinoids for AD within the last 6 months. * Use of biologics for AD within the past 3 months, or 5 half-lives (whichever is longer). * Subjects who have poor skin condition within 5 cm of the target lesion. * Subjects who are current drug or alcohol abusers; have a history of immunodeficiency disease; or are a poor medical risk because of other systemic diseases or active uncontrolled infections. * Subjects with an unstable medical condition or a medical condition not adequately controlled with standard medical therapy. * Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 30 days. * Subjects who have a clinically significant laboratory value at screening.